Navigation Links
Isis Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
Date:3/30/2011

CARLSBAD, Calif., March 30, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Needham's 10th Annual Healthcare Conference on Wednesday, April 06, 2011 at 10:40 a.m. ET at the New York Palace Hotel.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Today the U.S. Food and Drug ... the prevention of serogroup B meningococcal disease ... vaccine Trumenba®, which received FDA approval in October, represent ... disease. "I have heard over and ...
(Date:1/23/2015)... WASHINGTON , Jan. 23, 2015  A new analysis ... Part D 2015 enrollment data shows that 81 percent ... convenient access and extra discounts at certain pharmacies. The ... "Preferred pharmacy plans are now the foundation of ...
(Date:1/23/2015)... Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) ... of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On January ... website reporting that Advaxis had misrepresented the clinical data ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... Adherence to strict outcome requirements imposed by the ... an adverse effect on liver transplantation centers performing ... according to researchers at Northwestern University. According to ... aim to enhance post-transplant outcomes, the inadequately risk-adjusted ...
... 5, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... further clarity and context surrounding the risk for ... with KRYSTEXXA® (pegloticase) in the treatment of refractory ... the American College of Rheumatology (ACR) Annual Scientific ...
Cached Medicine Technology:Study Calls for Modification of CMS Conditions of Participation to Preserve Access to Life-Saving Liver Transplantations under Less than Optimal Conditions 2Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 2Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 3Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 4Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 5Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 6Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 7Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 8
(Date:1/22/2015)... 2015 Deer Path of Huntley -- ... Day Happy Hour from 3 p.m. to 4 p.m. on Feb. ... in Huntley, Illinois, serves adults with physical disabilities between the ages ... Valentine's Day treats, games and sweetheart-themed karaoke. , For more information ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader ... designers are thrilled to have it lead the wedding dress ... collection of prom dresses for the global market. , “The ... vision and he focuses on continuing the goal of operational ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... WASHINGTON, July 31 Speaker Nancy Pelosi issued the following statement ... to pass the America,s Affordable Health Choices Act, the third House ... and Means Committee and Education and Labor Committee approved the bill ... than 60 years, we have tried as a nation to make ...
... , WASHINGTON, July 31 ... "The Importance of a Cost Control Enforcement Entity In ... President Obama,s proposed Independent Medicare Advisory Council (IMAC). The ... experts who would routinely review Medicare spending and provide ...
... childhood cancer neuroblastoma are eight times more likely to ... and more likely to have lower incomes than their ... in the Journal of the National Cancer Institute ... exists on the long-term outcomes for neuroblastoma survivors. ...
... Hanger Orthopedic Group, Inc. (NYSE: HGR ) is ... Hanger Orthopedic Group, Inc. to "B1" from "B2." Moody,s also ... "Ba2" from "Ba3" and senior unsecured debt to "B3" from "Caa1." ... , "We are extremely pleased with the Moody,s upgrade ...
... , WASHINGTON, July 31 On behalf ... Kathleen Novak, mayor, Northglenn, Colo., commends President Barack Obama, the ... Pensions Committee for making progress on efforts to enact legislation ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NLCLOGO ) , ...
... and social issues years later , FRIDAY, July 31 (HealthDay ... long-term health and social problems, according to a new study. ... been diagnosed with neuroblastoma -- a cancer that forms in ... with data on 3,899 siblings of children with cancer. Twenty ...
Cached Medicine News:Health News:Concord Coalition Releases Issue Brief on Administration's IMAC Proposal 2Health News:Long-term health and social outcomes for neuroblastoma survivors 2Health News:Hanger Orthopedic Group, Inc. Receives Upgrade From Moody's Investors Service 2Health News:National League of Cities Commends President and Congress on Work Towards Health Care Reform 2
... ScImage's PICOMEnterprise is a web-enabled ... custom reporting and custom workflow integration. ... captures, stores, distributes and archives images, ... any DICOM and many non-DICOM devices ...
... Blood Pressure Monitoring System (ABPM) allows health ... blood pressure throughout the day. ABPM therapy ... hypertension and the data generated can be ... compact monitor has sophisticated tracking capabilities to ...
... AutoPulse Resuscitation System consists of the portable ... and a rechargeable battery pack with a ... designed for adults with weight up to ... to 51.2 inches (76 to 130 cm) ...
... single information technology platform, the VERICIS ... from different sites (office, clinic, hospital) ... x-ray angiography, echo, nuclear, MR, hemodynamics, ... digital record on the cardiac patient. ...
Medicine Products: